Committee Composition

Below is a summary of our committee structure and membership information. To read more about any of the committees, click on committee names in the chart below.
Chairperson Chairperson Committee Member Member Financial Expert Financial Expert
 Audit CommitteeCompensation CommitteeNominating and Corporate Governance Committee
Outside Directors
Suzanne L. Bruhn, Ph.D. 
Suzanne L. Bruhn, Ph.D.
  Committee Member Chairperson
Russell J. Cox 
Russell J. Cox
Director, Executive Vice President and Chief Operating Officer of Jazz Pharmaceuticals


Russell J. Cox, is Executive Vice President and Chief Operating Officer of Jazz Pharmaceuticals. He has served in a variety of escalating senior management roles since joining the company in 2010, including Executive Vice President and Chief Commercial officer from March 2012 to May 2014. From January 2009 to January 2010, he was Senior Vice President and Chief Commercial Officer of Ipsen Group and from 2007 until December 2008, he was Vice President of Marketing at Tercica, Inc. (acquired by Ip... 
Committee Member Chairperson  
Sandy Mahatme Financial Expert
Sandy Mahatme
Director, Senior Vice President and Chief Financial Officer of Serepta Therapeutics


Sandy Mahatme is Senior Vice President and Chief Financial Officer of Serepta Therapeutics. From January 2006 to November 2012, Mr. Mahatme worked at Celgene Corporation, a biopharmaceutical company, where he served in various roles, including Senior Vice President of Corporate Development, Senior Vice President of Finance, Corporate Treasurer and Head of Tax. While at Celgene, Mr. Mahatme built the treasury and tax functions before establishing the Corporate Development Department, focused on s... 
Chairperson Committee Member  
Armen Shanafelt, Ph.D. 
Armen Shanafelt, Ph.D.
Director, Lilly Ventures


Dr. Shanafelt brings over 24 years of experience in the pharmaceutical, biotechnology, and diagnostic businesses to Lilly Ventures. Previous to joining Lilly Ventures, Armen was CSO responsible for the generation of the early biotherapeutic pipeline for Eli Lilly and Company, spanning the therapeutic areas of oncology, endocrine, and neuroscience. During his seven years with Lilly, the biotherapeutic group delivered over 20 molecules into clinic development. Dr. Shanafelt received his B.S. Degre... 
Committee Member   Committee Member